Sugi Predict

Sugi Predict / Compounds / SCHEMBL17143243

SCHEMBL17143243

SCHEMBL17143243

CC(C)CC(C)(N)COc1ccc(-c2ccnc(NC(=O)O)c2)nc1Cl

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 20/20 0.86
▸ DAPK1 P53355 3/20 0.86
▸ MKNK2 Q9HBH9 3/20 0.86
▸ BMP2K Q9NSY1 3/20 0.86
▸ MKNK1 Q9BUB5 3/20 0.86
▸ MYLK2 Q9H1R3 3/20 0.86
▸ DAPK3 O43293 2/20 0.86
▸ JAK2 O60674 2/20 0.86
▸ HIPK4 Q8NE63 2/20 0.86
▸ CIT O14578 2/20 0.86
▸ MAP2K1 Q02750 1/20 0.86
▸ PKN2 Q16513 1/20 0.86
▸ TLK2 Q86UE8 1/20 0.86
▸ STK39 Q9UEW8 1/20 0.86
▸ TLK1 Q9UKI8 1/20 0.86
▸ GAK O14976 3/20 0.74
▸ HTR2B P41595 1/20 0.74
▸ KCNH2 Q12809 1/20 0.74
▸ ROCK2 O75116 2/20 0.68
▸ TYRO3 Q06418 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19901200 0.93 AAK1 (1.00) AAK1DAPK1MKNK2BMP2KMKNK1
SCHEMBL17155348 0.93 AAK1 (1.00) AAK1DAPK1MKNK2BMP2KMKNK1
SCHEMBL30059552 0.93 AAK1 (1.00) AAK1DAPK1MKNK2BMP2KMKNK1
SCHEMBL17143706 0.90 AAK1 (0.86) AAK1DAPK1MKNK2BMP2KMKNK1
SCHEMBL20446811 0.87 AAK1 (0.85) AAK1DAPK1MKNK2BMP2KMKNK1
SCHEMBL17143842 0.87 AAK1 (0.85) AAK1DAPK1MKNK2BMP2KMKNK1
SCHEMBL17143866 0.87 AAK1 (0.84) AAK1DAPK1MKNK2BMP2KMKNK1
SCHEMBL30059562 0.85 AAK1 (1.00) AAK1DAPK1MKNK2BMP2KMKNK1
SCHEMBL17155572 0.85 AAK1 (1.00) AAK1DAPK1MKNK2BMP2KMKNK1
SCHEMBL19901194 0.85 AAK1 (1.00) AAK1DAPK1MKNK2BMP2KMKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3126351-B1 BIARYL KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-09-19 — — EP claimed
US-9902722-B2 Biaryl kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 — — US claimed
US-20170183340-A1 BIARYL KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-06-29 — — US claimed
WO-2023200892-A1 COMPOUNDS AND METHODS FOR TREATING SPASTICITY LEXICON PHARMACEUTICALS, INC. (US) 2023-10-19 — — WO disclosed
US-20230330074-A1 COMPOUNDS AND METHODS FOR TREATING SPASTICITY LEXICON PHARMACEUTICALS, INC. (US) 2023-10-19 — — US disclosed
US-11730723-B2 Compounds and methods for treating viral infections LEXICON PHARMACEUTICALS, INC. (US) 2023-08-22 — — US disclosed
US-20220054464-A1 COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS OXFORD FINANCE LLC 2022-02-24 — — US disclosed
US-20210277001-A1 BIARYL KINASE INHIBITORS Cosmic Pet LLC 2021-09-09 — — US disclosed
US-10981910-B2 Biaryl kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2021-04-20 — — US disclosed
US-20200317671-A1 BIARYL KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-10-08 — — US disclosed
US-10723734-B2 Biaryl kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2020-07-28 — — US disclosed
US-10155760-B2 Biaryl kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-12-18 — — US disclosed
US-20180346440-A1 BIARYL KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-12-06 — — US disclosed
EP-3126351-B1 BIARYL KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-09-19 — — EP disclosed
EP-3356340-A1 BIARYL KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2018-08-08 — — EP disclosed
US-20180134704-A1 BIARYL KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-05-17 — — US disclosed
US-9902722-B2 Biaryl kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 — — US disclosed
US-20170183340-A1 BIARYL KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-06-29 — — US disclosed
EP-3126351-A1 BIARYL KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2017-02-08 — — EP disclosed
WO-2015153720-A1 BIARYL KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2015-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134704-A1 BIARYL KINASE INHIBITORS AAK1, NCK1, MARCKS AAK1 1/4885DAPK1 9/4885MKNK2 45/4885
US-10981910-B2 Biaryl kinase inhibitors AAK1, NCK1, MARCKS AAK1 1/4885DAPK1 9/4885MKNK2 45/4885
US-20230330074-A1 COMPOUNDS AND METHODS FOR TREATING SPASTICITY SMN1; SMN2, MUSK, GAB1 AAK1 62/4885DAPK1 287/4885MKNK2 369/4885
US-20210277001-A1 BIARYL KINASE INHIBITORS AAK1, NCK1, MARCKS AAK1 1/4885DAPK1 9/4885MKNK2 45/4885
US-20220054464-A1 COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS EIF2AK2, SARS1, MAVS AAK1 147/4885DAPK1 211/4885MKNK2 947/4885
US-20200317671-A1 BIARYL KINASE INHIBITORS AAK1, NCK1, MARCKS AAK1 1/4885DAPK1 9/4885MKNK2 45/4885
US-20170183340-A1 BIARYL KINASE INHIBITORS AAK1, NCK1, MARCKS AAK1 1/4885DAPK1 9/4885MKNK2 45/4885
US-11730723-B2 Compounds and methods for treating viral infections EIF2AK2, SARS1, MAVS AAK1 147/4885DAPK1 211/4885MKNK2 947/4885
US-20180346440-A1 BIARYL KINASE INHIBITORS AAK1, CAMKK1, CAMKK2 AAK1 1/4885DAPK1 15/4885MKNK2 31/4885
US-10155760-B2 Biaryl kinase inhibitors AAK1, NCK1, MARCKS AAK1 1/4885DAPK1 9/4885MKNK2 45/4885
US-10723734-B2 Biaryl kinase inhibitors AAK1, NCK1, MARCKS AAK1 1/4885DAPK1 9/4885MKNK2 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.